Show
Sort by
-
- Journal Article
- A2
- open access
EUFOREA summit in Brussels 2023 : inspiring the future of allergy & respiratory care
-
- Journal Article
- A1
- open access
Association between outdoor air pollution and chronic rhinosinusitis patient reported outcomes
-
- Miscellaneous
- open access
Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps
-
- Journal Article
- A1
- open access
Dupilumab in CRSwNP : responder analysis using clinically meaningful efficacy outcome thresholds
-
- Journal Article
- A1
- open access
AROMA : real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps
-
- Journal Article
- A1
- open access
Estimating clinically meaningful change of efficacy outcomes in inadequately controlled chronic rhinosinusitis with nasal polyposis
-
Role of biologics in chronic rhinosinusitis with nasal polyposis : state of the art review
-
Rapid and sustained effects of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps : analysis of the SINUS-24 and SINUS-52 phase 3 trails
(2021) AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. In American Journal of Respiratory and Critical Care Medicine 203(9, supplement S). p.A1345-A1345 -
Health-related quality of life impairment among patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 trial
(2021) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. In Journal of Allergy and Clinical Immunology 147(2). p.AB133-AB133 -
- Journal Article
- A1
- open access
Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps
-
Surgery in nasal polyp patients : outcome after a minimum observation of 10 years
-
SNOT-22 items and association with objective measures in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from SINUS-24 and SINUS-52 trials
-
EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics : definitions and management
-
A 300 IR sublingual tablet is an effective, safe treatment for house dust mite induced allergic rhinitis : an international, double-blind, placebo-controlled, randomized phase III clinical trial
-
- Journal Article
- A1
- open access
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma
-
- Journal Article
- A1
- open access
Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP
-
International consensus statement on allergy and rhinology : rhinosinusitis 2021
-
Omalizumab is associated with a reduced need for surgery in patients with nasal polyposis
-
- Journal Article
- A1
- open access
Allergic respiratory disease care in the COVID-19 era : a EUFOREA statement
-
- Journal Article
- A1
- open access
COVID-19 and olfactory dysfunction : an ENT perspective to the current COVID-19 pandemic